BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Peptimmune, Inc. 

64 Sidney Street
Suite 380
Cambridge  Massachusetts  02139-4136  U.S.A.
Phone: 617-715-8000 Fax: 617-661-8855


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Medivir AB  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Novartis Corporation  Exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune’s multiple sclerosis drug candidate.





 Company News
Merck Serono Buys Potential Copaxone Competitor from Bankrupt Peptimmune, Inc. 9/19/2011 8:20:03 AM    More...
Peptimmune, Inc. Files Under Chapter 7 3/23/2011 8:16:06 AM    More...
Peptimmune, Inc. Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone 10/4/2010 10:06:16 AM    More...
Peptimmune, Inc. Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 8/25/2009 10:49:29 AM    More...
Peptimmune, Inc. Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis; Payments Could Total More Than $500 Million 1/15/2009 8:20:08 AM    More...
'Unprecedented' Biotech Bankruptcies Erupt Amid Finance Crisis 11/21/2008 12:59:34 PM    More...
Peptimmune, Inc. Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis 9/17/2008 8:26:00 AM    More...
Peptimmune, Inc. Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 7/31/2008 7:55:58 AM    More...
Peptimmune, Inc. Announces the Second Close of Series D Private Financing 7/16/2008 11:13:45 AM    More...
Peptimmune, Inc. Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients 6/17/2008 9:55:20 AM    More...
123

//-->